Osocimab, formerly known as BAY 1213790, represents a unique monoclonal protein currently in clinical development for the treatment of multiple hematologic tumors. This molecule specifically targets CD38, a cell receptor present on abnormal cells in illnesses like multiple myeloma and acute myeloid leukemia. Preclinical research have indicated i… Read More